United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hydrochloride tablets are indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most freguently used regimens have been the following: -  ethambutol hydrochloride tablets plus isoniazid -  ethambutol hydrochloride tablets plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hydrochloride tablets should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals holdings ltd - ethambutol hydrochloride - oral tablet - 400mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals holdings ltd - ethambutol hydrochloride - oral tablet - 100mg

Kenya - English - Pharmacy and Poisons Board

ethambutol hydrochloride - tablet - ethambutol hydrochloride 800mg - ethambutol

Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare ltd - ethambutol hydrochloride - film-coated tablet - 100 milligram(s) - other drugs for treatment of tuberculosis; ethambutol

Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare ltd - ethambutol hydrochloride - film-coated tablet - 400 milligram(s) - other drugs for treatment of tuberculosis; ethambutol

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - ethambutol hydrochloride - oral tablet - 400mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - ethambutol hydrochloride - oral tablet - 100mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride tablets usp are indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: ethambutol hydrochloride tablets usp plus isoniazid ethambutol hydrochloride tablets usp plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hydrochloride tablets usp should be combined with at least one of the second line drugs not previously administered to the patient and to which bact

United States - English - NLM (National Library of Medicine)

epic pharma, llc - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride tablets, usp are indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: ethambutol hydrochloride, usp plus isoniazid ethambutol hydrochloride, usp plus isoniazid plus streptomycin in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hydrochloride should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with ethambutol hydrochloride have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilized. ethambutol hydrochloride is contraindicated in patients who are known to be hypersensitive to this drug. it is also contraindicated in patients with known optic neuritis unless clinical judgment determines that it may be used. ethambutol hydrochloride is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients).